Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Indications/Uses

SOLIRIS is indicated in adults and children for the treatment of patients with: Paroxysmal nocturnal haemoglobinuria (PNH).
Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see Pharmacology: Pharmacodynamics under Actions).
Atypical Haemolytic Uremic Syndrome (aHUS) (see Pharmacology: Pharmacodynamics under Actions).
SOLIRIS is indicated in adults for the treatment of patients with: Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see Pharmacology: Pharmacodynamics under Actions).
Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive (see Pharmacology: Pharmacodynamics under Actions).

Soliris Indications/Uses

eculizumab

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma